ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
Open Access
- 20 December 2021
- Vol. 25 (1) , 103670
Abstract
No abstract availableKeywords
Funding Information
- NHLBI (R35HL139930)
- Tulane University (MDR504)
- National Institute of Allergy and Infectious Diseases (272201400008C, 75N93021C00014)
- Defense Advanced Research Projects Agency (HR0011-19-2-0020)
- Pfizer
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health (R21OD024931)
- JPB Foundation (2020-215611 (5384))
This publication has 27 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertensionEuropean Respiratory Journal, 2018
- A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromeCritical Care, 2017
- Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2aMolecular Immunology, 2015
- Linking endothelial dysfunction with endothelial cell activationJournal of Clinical Investigation, 2013
- Protein Structure Prediction Using Threading2008
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- Adenovirus-Mediated Blockade Of Tumor Necrosis Factor In Mice Protects Against Endotoxic Shock Yet Impairs Pulmonary Host DefenseThe Journal of Infectious Diseases, 1995